JNJ-7777120

JNJ-7777120
Clinical data
Other names	1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine
Identifiers
	IUPAC name 5-chloro-2-[(4-methylpiperazin-1-yl)carbonyl]-1H-indole;
CAS Number	459168-41-3 ;
PubChem CID	4908365;
IUPHAR/BPS	1278;
ChemSpider	4090750 ;
UNII	4H1AU2V37X;
ChEMBL	ChEMBL129198 ;
CompTox Dashboard (EPA)	DTXSID20963461 ;
ECHA InfoCard	100.164.683
Chemical and physical data
Formula	C14H16ClN3O
Molar mass	277.75 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C3CN(C)CCN3C(=O)c(cc1c2)[nH]c1ccc2Cl;
	InChI InChI=1S/C14H16ClN3O/c1-17-4-6-18(7-5-17)14(19)13-9-10-8-11(15)2-3-12(10)16-13/h2-3,8-9,16H,4-7H2,1H3 ; Key:HUQJRYMLJBBEDO-UHFFFAOYSA-N ;
	(what is this?) (verify)

JNJ-7777120 was a drug being developed by Johnson & Johnson Pharmaceutical Research & Development which acts as a potent and selective antagonist at the histamine H₄ receptor.^[1] It has anti-inflammatory effects,^[2] and has been demonstrated to be superior to traditional (H1) antihistamines in the treatment of pruritus (itching).^[3] The drug was abandoned because of its short in vivo half-life and hypoadrenocorticism toxicity in rats and dogs, that prevented advancing it into clinical studies.^[4]